In this article by The Medicine Maker, Dr. Asma Patel, VP of Integrated Development Services at Quotient Sciences discusses how accelerating first-in-human (FiH) clinical trials is crucial in drug development, especially for orphan drugs treating rare diseases.
Asma points out how a simplified formulation approach, such as a drug-in-capsule method, can streamline the process.
Continue reading the full article on The Medicine Maker